NewGen reports $9.9M net profit and $32.7M assets in FY2025, driven by strategic acquisitions and diversification.

NewGenIVF Group announced a strong fiscal year 2025 with total assets reaching $32.7 million, up from $3.6 million the previous year, and a net profit of $9.9 million mainly due to gains from acquiring Nodexus and Microsort businesses. The company also completed a $17.9 million valuation of advanced cytometry intellectual property, contributing to a $19.2 million bargain purchase gain. NewGen is advancing its diversification strategy through digital assets and health supplements, supported by a $2 million share repurchase program reflecting management confidence. These results highlight NewGen's successful transformation and position it for continued growth across real estate, digital innovation, and healthcare sectors.